“Supply will only be limited by production.”

I see that we agree supply will be an issue. Advanced diagnostics will assist in getting the limited supply of leronlimab to those who need it most while production is increased. Once supply better aligns with demand, leronlimab can be more widely prescribed at the point of diagnosis, or shortly later, to those with risk factors for hospitalization. Even then, individuals who could progress to S/C will be missed because risk factors alone don’t encompass 100% of the S/C population. Therefore, the use of diagnostics will still be needed and will increase sales of leronlimab by is identifying more patients who need the medication.